Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind study of V114 versus PNEUMOVAX 23 in healthy adults
2011-004542-18Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease, invasive pneumococcal disease (IPD) and Pneumococcal pneumonia (PP) (2 arms), sponsored by Merck & Co. Primary endpoint: Ratio of serotype-specific pneumococcal capsular polysaccharide IgG GMCs [V114 / PNEUMOVAX 23]. Started Feb 2012; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal diseaseinvasive pneumococcal disease (IPD)Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on 2011-004542-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004542-18.